Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
YhTVwJFN701dJgPS
